Literature DB >> 2883664

Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions.

G B Freeman, K A Sherman, G E Gibson.   

Abstract

Nicotine's action on the central nervous system is complex and likely involves an interaction of neurotransmitters. To determine the time after administration of nicotine and dosage for neurochemical studies, locomotor activity of CD-1 mice was determined at 5 min intervals between 0-60 min. A low nicotine dosage (0.05 mg/kg) did not alter activity 5-15 min after drug injection, but increased activity 28% at 15-25 min post-injection. A high dosage (0.8 mg/kg) reduced total distance 62% and rearing 87% at 5-15 min; at 15-25 minutes total distance declined 56% and rearing 69%; all measures returned to control values after 30 minutes; rearing then increased at 40 min after nicotine. Pretreatment (15 min before nicotine) with mecamylamine (1.0 mg/kg), but not hexamethonium (1.0 mg/kg), prevented the depressant effect of nicotine. Dopamine (DA) and its metabolites as well as acetylcholine (ACh) synthesis were measured at the point of nicotine's maximal depressant action. Striatal levels of dihydroxyphenylacetic acid (DOPAC) were increased and ACh utilization was reduced in striatum (-25%) and cortex (-24%) 10 min after nicotine (0.8 mg/kg). Mecamylamine, while preventing the depressant effect of nicotine on locomotor activity, did not alter its effects on DA metabolism. These results demonstrate that the behavioral outcome of acute nicotine treatment is time and dose-dependent. Nicotine's depressant action appears not to be due to altered DA but may be related to changes in carbohydrate and acetylcholine metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883664     DOI: 10.1016/0091-3057(87)90123-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs.

Authors:  L Beani; S Tanganelli; T Antonelli; L Ferraro; M Morari; P Spalluto; A Nordberg; C Bianchi
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

2.  MD-354 selectively antagonizes the antinociceptive effects of (-)nicotine in the mouse tail-flick assay.

Authors:  Małgorzata Dukat; Anna Wesołowska; Genevieve Alley; Shawquia Young; Galya R Abdrakhmanova; Hernán A Navarro; Richard Young; Richard A Glennon
Journal:  Psychopharmacology (Berl)       Date:  2010-04-30       Impact factor: 4.530

3.  Harmane Potentiates Nicotine Reinforcement Through MAO-A Inhibition at the Dose Related to Cigarette Smoking.

Authors:  Zheng Ding; Xiangyu Li; Huan Chen; Hongwei Hou; Qingyuan Hu
Journal:  Front Mol Neurosci       Date:  2022-06-27       Impact factor: 6.261

4.  Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice.

Authors:  K Yano; K Koda; Y Ago; H Kobayashi; T Kawasaki; K Takuma; T Matsuda
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

5.  Bupropion differentially alters the aversive, locomotor and rewarding properties of nicotine in CD-1 mice.

Authors:  Anthony S Rauhut; Michael Hawrylak; Stacey K Mardekian
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

6.  Activation of the GABA(B) Receptor Prevents Nicotine-Induced Locomotor Stimulation in Mice.

Authors:  Carla Lobina; Mauro A M Carai; Wolfgang Froestl; Claudia Mugnaini; Serena Pasquini; Federico Corelli; Gian Luigi Gessa; Giancarlo Colombo
Journal:  Front Psychiatry       Date:  2011-12-30       Impact factor: 4.157

7.  Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice.

Authors:  Toyoshi Umezu
Journal:  ISRN Pharmacol       Date:  2012-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.